Today, AtheroNova Inc. (AHRO-OTC) announced that it has initiated a Phase I clinical trial with AHRO-001, the Company’s lead compound. This milestone marks AtheroNova’s transition to a clinical-stage company. AHRO-001 is intended to treat and prevent atherosclerosis, a disease in which the buildup of cholesterol, fats, or other fatty substances along the walls of the arteries causes thickening, blockage, and hardening. Atherosclerotic plaque is the main cause of cardiovascular disease. 

Currently, lipid regulators, specifically statins, are the most effective method for reducing serum cholesterol levels. However, at commonly prescribed dosage levels, statins are ineffective at reducing plaque, carry significant drawbacks in their tolerability, and may pose complications resulting from long-term use. Despite these disadvantages, the global market for lipid regulators was $38.7 billion as of 2011 (Source: IMS Health).

If you will be at OneMedForumNY 2013 this week, you are invited to attend the Fund Managers Unplugged panel as veteran fund managers, including Crystal Research CEO Jeffrey Kraws, explore the state of financing in the life sciences arena and discuss the successful “picks” made during OneMedForumSF 2013 this past January.

Check out our YouTube page for video highlights from the first “Fund Managers Unplugged” event held in January 2013, which include Jeff Kraws' initial stock picks, Gilead Sciences (GILD-NASDAQ) and ISIS Pharmaceuticals (ISIS-NASDAQ), which are up 23% and 107% respectively since the first panel!

This afternoon we released our first Executive Informational Overview on Convoy Therapeutics, Inc., a closely held, late-stage biotechnology company developing a next-generation drug delivery technology. The report details Convoy's business, product development and R&D efforts, growth strategies and important milestones, management backgrounds, potential competition, and market opportunities, among many other factors that investors and stakeholders may find relevant.